SRR1487321
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.419
- PANCREAS_BETA_CELLS+0.393
- HEDGEHOG_SIGNALING+0.374
- XENOBIOTIC_METABOLISM+0.262
- MYOGENESIS+0.229
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- ESTROGEN_RESPONSE_LATE+0.161
- OXIDATIVE_PHOSPHORYLATION+0.126
- ESTROGEN_RESPONSE_EARLY+0.113
- APICAL_SURFACE+0.108
Top 10 suppressed
- MYC_TARGETS_V1-0.565
- E2F_TARGETS-0.505
- G2M_CHECKPOINT-0.502
- INTERFERON_ALPHA_RESPONSE-0.502
- PROTEIN_SECRETION-0.456
- TGF_BETA_SIGNALING-0.451
- UNFOLDED_PROTEIN_RESPONSE-0.448
- MITOTIC_SPINDLE-0.406
- MYC_TARGETS_V2-0.382
- DNA_REPAIR-0.378
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1433431 | GTEX | — | 0.955 |
| 2 | SRR1354910 | GTEX | — | 0.939 |
| 3 | SRR1314958 | GTEX | — | 0.936 |
| 4 | SRR1405007 | GTEX | — | 0.934 |
| 5 | SRR1453145 | GTEX | — | 0.929 |
| 6 | SRR1316297 | GTEX | — | 0.928 |
| 7 | SRR1480365 | GTEX | — | 0.926 |
| 8 | SRR1417827 | GTEX | — | 0.926 |
| 9 | SRR1441546 | GTEX | — | 0.922 |
| 10 | SRR1474333 | GTEX | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.419 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.393 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.374 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.262 | Inavolisib | — uncovered |
| MYOGENESIS | 0.229 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.161 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.126 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.113 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.108 | Temsirolimus | — uncovered |
| COAGULATION | 0.101 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.091 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.052 | Inavolisib | — uncovered |
| COMPLEMENT | 0.028 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.025 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.022 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |